FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379280950> ?p ?o ?g. }

• W4379280950 endingPage "e20508" @default.
• W4379280950 startingPage "e20508" @default.
• W4379280950 abstract "e20508 Background: This study aimed to explore the value of metabolic features in predicting the response to induction immuno-chemotherapy in locally advanced NSCLC, using dynamic total body [ 18 F]FDG PET/CT. Methods: The LA-NSCLC patients who received two cycles of induction immuno-chemotherapy were analyzed in the study. The 60-minute dynamic total body [ 18 F]FDG PET/CT scan was administered before treatment. The primary tumors (PTs) were manually delineated. The metabolic features including the Patlak-Ki, Patlak-Intercept, the SUV max , metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of PTs were evaluated. Using the Patlak graphical analysis, the Patlak-Ki of PTs was calculated from the 20-60 minutes frames. The Laplacian feature importance scores was used to select the best feature and an unsupervised K-Means method was applied to cluster patients. ROC curve was used to examine the effect of selected metabolic feature in predicting tumor response to treatment. The targeted next generation sequencing on 1021 genes was conducted. The expressions of CD68, CD86, CD163, CD206, CD33, CD34, Ki67 and VEGFA were assayed by immunohistochemistry. The independent samples t test and the Mann-Whitney U test were applied in the intergroup comparison. Results: Thirty-seven LA-NSCLC patients were analyzed between September 2020 and November 2021. All patients received two cycles of induction chemotherapy combined with Nivolumab/ Camrelizumab. The Laplacian scores showed that the Patlak-Ki of PTs had the highest importance for patient clustering, and the unsupervised K-Means derived decision boundary of Patlak-Ki was 2.779 ml/min/100g. Then Patients were divided into a high FDG Patlak-Ki (H-FDG-Ki, Patlak-Ki > 2.779 ml/min/100g) group (n = 23) and a low FDG Patlak-Ki (L-FDG-Ki, Patlak-Ki ≤ 2.779 ml/min/100g) group (n = 14). The ORR to induction immuno-chemotherapy was 67.6% (25/37) in the whole cohort, with 87% (20/23) in H-FDG-Ki group and 35.7% (5/14) in the L-FDG-Ki group (P = 0.001). The sensitivity and specificity of Patlak-Ki in predicting the treatment response were 80% and 75%, respectively [AUC = 0.775 (95%CI 0.605-0.945)]. The expression of CD3 + /CD8 + T cells and CD86 + /CD163 + /CD206 + macrophages were higher in the H-FDG-Ki group, while Ki67, CD33 + myeloid cells, CD34 + micro-vessel density (MVD) and tumor mutation burden (TMB) were comparable between the two groups. Conclusions: The total body [ 18 F]FDG PET/CT scanner performed a dynamic acquisition of the entire body and clustered LA-NSCLC patients into H-FDG-Ki and L-FDG-Ki groups based on the Patlak-Ki. H-FDG-Ki patients had better response to induction immuno-chemotherapy and higher immune cells infiltrations in the PTs than L-FDG-Ki patients. Further studies in a large patient cohort are warranted." @default.
• W4379280950 created "2023-06-05" @default.
• W4379280950 creator A5000117252 @default.
• W4379280950 creator A5002696952 @default.
• W4379280950 creator A5009101039 @default.
• W4379280950 creator A5017366969 @default.
• W4379280950 creator A5032937513 @default.
• W4379280950 creator A5040308577 @default.
• W4379280950 creator A5044301848 @default.
• W4379280950 creator A5046479650 @default.
• W4379280950 creator A5050602131 @default.
• W4379280950 creator A5054851994 @default.
• W4379280950 creator A5058762407 @default.
• W4379280950 creator A5059204360 @default.
• W4379280950 creator A5066773067 @default.
• W4379280950 creator A5071191374 @default.
• W4379280950 creator A5071441248 @default.
• W4379280950 creator A5073568638 @default.
• W4379280950 creator A5078840423 @default.
• W4379280950 creator A5091584882 @default.
• W4379280950 creator A5092083201 @default.
• W4379280950 date "2023-06-01" @default.
• W4379280950 modified "2023-09-23" @default.
• W4379280950 title "Value of Patlak-Ki from ultra-high sensitivity dynamic total body [¹⁸F]FDG PET/CT for evaluation of treatment response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer (LA-NSCLC) patients." @default.
• W4379280950 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e20508" @default.
• W4379280950 hasPublicationYear "2023" @default.
• W4379280950 type Work @default.
• W4379280950 citedByCount "0" @default.
• W4379280950 crossrefType "journal-article" @default.
• W4379280950 hasAuthorship W4379280950A5000117252 @default.
• W4379280950 hasAuthorship W4379280950A5002696952 @default.
• W4379280950 hasAuthorship W4379280950A5009101039 @default.
• W4379280950 hasAuthorship W4379280950A5017366969 @default.
• W4379280950 hasAuthorship W4379280950A5032937513 @default.
• W4379280950 hasAuthorship W4379280950A5040308577 @default.
• W4379280950 hasAuthorship W4379280950A5044301848 @default.
• W4379280950 hasAuthorship W4379280950A5046479650 @default.
• W4379280950 hasAuthorship W4379280950A5050602131 @default.
• W4379280950 hasAuthorship W4379280950A5054851994 @default.
• W4379280950 hasAuthorship W4379280950A5058762407 @default.
• W4379280950 hasAuthorship W4379280950A5059204360 @default.
• W4379280950 hasAuthorship W4379280950A5066773067 @default.
• W4379280950 hasAuthorship W4379280950A5071191374 @default.
• W4379280950 hasAuthorship W4379280950A5071441248 @default.
• W4379280950 hasAuthorship W4379280950A5073568638 @default.
• W4379280950 hasAuthorship W4379280950A5078840423 @default.
• W4379280950 hasAuthorship W4379280950A5091584882 @default.
• W4379280950 hasAuthorship W4379280950A5092083201 @default.
• W4379280950 hasConcept C126322002 @default.
• W4379280950 hasConcept C199374082 @default.
• W4379280950 hasConcept C2775842073 @default.
• W4379280950 hasConcept C2776611710 @default.
• W4379280950 hasConcept C2776694085 @default.
• W4379280950 hasConcept C2989005 @default.
• W4379280950 hasConcept C58471807 @default.
• W4379280950 hasConcept C71924100 @default.
• W4379280950 hasConceptScore W4379280950C126322002 @default.
• W4379280950 hasConceptScore W4379280950C199374082 @default.
• W4379280950 hasConceptScore W4379280950C2775842073 @default.
• W4379280950 hasConceptScore W4379280950C2776611710 @default.
• W4379280950 hasConceptScore W4379280950C2776694085 @default.
• W4379280950 hasConceptScore W4379280950C2989005 @default.
• W4379280950 hasConceptScore W4379280950C58471807 @default.
• W4379280950 hasConceptScore W4379280950C71924100 @default.
• W4379280950 hasIssue "16_suppl" @default.
• W4379280950 hasLocation W43792809501 @default.
• W4379280950 hasOpenAccess W4379280950 @default.
• W4379280950 hasPrimaryLocation W43792809501 @default.
• W4379280950 hasRelatedWork W136763593 @default.
• W4379280950 hasRelatedWork W1569185783 @default.
• W4379280950 hasRelatedWork W1982187894 @default.
• W4379280950 hasRelatedWork W2111347914 @default.
• W4379280950 hasRelatedWork W2117290479 @default.
• W4379280950 hasRelatedWork W2138033649 @default.
• W4379280950 hasRelatedWork W2898897263 @default.
• W4379280950 hasRelatedWork W2914849423 @default.
• W4379280950 hasRelatedWork W3134813758 @default.
• W4379280950 hasRelatedWork W46874381 @default.
• W4379280950 hasVolume "41" @default.
• W4379280950 isParatext "false" @default.
• W4379280950 isRetracted "false" @default.
• W4379280950 workType "article" @default.